Literature DB >> 3927987

Limited nonenzymatic glucosylation of low-density lipoprotein does not alter its catabolism in tissue culture.

E Schleicher, B Olgemöller, J Schön, T Dürst, O H Wieland.   

Abstract

This study examines the effects of various degrees of chemical modification of low-density lipoprotein (LDL) on its catabolism by various cell types. Moderate glucosylation of LDL does not alter its interaction with the high-affinity receptor present on human fibroblasts at concentration of 5-2000 micrograms LDL-cholesterol/ml. Only heavily glucosylated LDL (more than 12 lysine residues glucosylated per apolipoprotein B) or LDL glucosylated in the presence of Na(CN)BH3, i.e., conditions not expected to occur in diabetes, inhibit receptor-mediated internalisation and degradation. Moderately glucosylated LDL is also readily recognized by cultured rat hepatocytes and porcine endothelial cells. Human monocyte-derived macrophages accumulate cholesteryl ester when incubated with acetylated LDL for 12 days but no enhanced cholesteryl ester formation was found when native or glucosylated LDL (3.3 lysines glucosylated per apolipoprotein B) were used.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3927987     DOI: 10.1016/0167-4889(85)90069-2

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  3 in total

1.  Pathophysiological concentrations of glucose promote oxidative modification of low density lipoprotein by a superoxide-dependent pathway.

Authors:  M Kawamura; J W Heinecke; A Chait
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

Review 2.  [The significance of the Maillard reaction in human physiology].

Authors:  E Schleicher
Journal:  Z Ernahrungswiss       Date:  1991-02

3.  Metabolism of very low- and low-density lipoproteins isolated from normolipidaemic type 2 (non-insulin-dependent) diabetic patients by human monocyte-derived macrophages.

Authors:  R L Klein; T J Lyons; M F Lopes-Virella
Journal:  Diabetologia       Date:  1990-05       Impact factor: 10.122

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.